Management of Diarrhea in Patients With Carcinoid Syndrome
| Autor: | Thorvardur R. Halfdanarson, Magnus Halland, Thomas M. O'Dorisio, Boris G. Naraev, Amy J. Purvis, Daniel M. Halperin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Diarrhea
medicine.medical_specialty 5-HTP - 5-hydroxytryptophan Endocrinology Diabetes and Metabolism Carcinoid tumors Cost-Benefit Analysis Reviews carcinoid syndrome telotristat Neuroendocrine tumors Gastroenterology 5-HIAA - 5-hydroxyindoleacetic acid QoL - quality of life Diagnosis Differential 03 medical and health sciences 0302 clinical medicine Endocrinology SSA - selective somatostatin analogue GI - gastrointestinal Stomach Neoplasms Internal medicine Intestinal Neoplasms Internal Medicine medicine carcinoid tumors Humans NET - neuroendocrine tumors Malignant Carcinoid Syndrome Hepatology business.industry Bile acid malabsorption medicine.disease Short bowel syndrome Debulking somatostatin analogs Steatorrhea Pancreatic Neoplasms FDA - US Food and Drug Administration Neuroendocrine Tumors 030220 oncology & carcinogenesis Quality of Life 030211 gastroenterology & hepatology medicine.symptom business Somatostatin Carcinoid syndrome CS - carcinoid syndrome |
| Zdroj: | Pancreas |
| ISSN: | 1536-4828 0885-3177 |
| Popis: | Neuroendocrine tumors (NETs) arise from enterochromaffin cells found in neuroendocrine tissues, with most occurring in the gastrointestinal tract. The global incidence of NETs has increased in the past 15 years, likely due to better diagnostic methods. Small-bowel NETs are frequently associated with carcinoid syndrome (CS). Carcinoid syndrome diarrhea occurs in 80% of CS patients and poses a substantial symptomatic and economic burden. Patients with CS diarrhea frequently suffer from diarrhea and flushing and report corresponding impairment in quality of life, requiring substantial changes in daily activities and lifestyle. Treatment paradigms range from surgical debulking to liver-directed therapies to treatment with somatostatin analogs, nonspecific anti-diarrheal agents, and a tryptophan hydroxylase inhibitor. Other causes of diarrhea, including steatorrhea, short bowel syndrome, and bile acid malabsorption, should be considered in NET patients with refractory diarrhea. More therapeutic options are needed for symptomatic management of patients with NETs, and better understanding of the pathophysiology can empower clinicians with improved patient care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|